Close Menu

Biomarker Discovery & Validation

News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.

The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.

The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.

The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.

The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.

The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.

Oct
21

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.